CARVYKTI DIN 02535270
Health Canada record
| Active ingredient(s) | CILTACABTAGENE AUTOLEUCEL 100000000 CELLS |
|---|---|
| Dosage form | Suspension |
| Route | Intravenous |
| Schedule | SCHEDULE D; PRESCRIPTION |
| Class | Human |
| ATC | L01XL05 CILTACABTAGENE AUTOLEUCEL |
| Original market date | |
| Current status date | 09-Feb-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Janssen Inc — licence 100239, currently licensed, last inspection rating C (2026-03-09).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 30099 | 2023-02-09 | New Drug Submission (NDS) |